lactic acid has been researched along with Pulmonary Hypertension in 21 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open label study of milrinone in neonates with persistent pulmonary hypertension of the newborn was conducted." | 9.17 | Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. ( Freeman, D; McNamara, PJ; Sahni, M; Shivananda, SP; Taddio, A, 2013) |
| " The aim of the present study was to examine the impact of a novel NHE1 inhibitor, sabiporide, on cardiovascular function, blood oxygen transportation, and inflammatory response in an experimental model of metabolic acidosis produced by hemorrhage-induced hypovolemia followed by an infusion of lactic acid." | 7.79 | Sabiporide improves cardiovascular function, decreases the inflammatory response and reduces mortality in acute metabolic acidosis in pigs. ( Abraham, WM; Kraut, JA; Wu, D, 2013) |
| "The experiments test if experimental PE causes red blood cell hemolysis, arginase release and depletion of l-arginine and determine if arginase inhibition preserves l-arginine and improves pulmonary hemodynamics during PE." | 7.78 | Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism. ( Das, SK; Fulkerson, MB; Gellar, MA; Kline, JA; Watts, JA, 2012) |
| "The present study is an attempt to leverage therapeutic benefits of curcumin in pulmonary hypertension by encapsulating it in biodegradable poly(lactide-co-glycolic) acid nanoparticles." | 7.78 | Tissue localization of nanoparticles is altered due to hypoxia resulting in poor efficacy of curcumin nanoparticles in pulmonary hypertension. ( Devadasu, VR; Ravi Kumar, MN; Wadsworth, RM, 2012) |
| "This study demonstrates that exogenous ADM prevents and reverses hypodynamic circulation, attenuates pulmonary hypertension, and limits lactic acidosis in ovine endotoxaemia." | 7.74 | Exogenous adrenomedullin prevents and reverses hypodynamic circulation and pulmonary hypertension in ovine endotoxaemia. ( Booke, M; Ertmer, C; Hucklenbruch, C; Lange, M; Morelli, A; Rehberg, S; Van Aken, H; Westphal, M, 2007) |
| "An open label study of milrinone in neonates with persistent pulmonary hypertension of the newborn was conducted." | 5.17 | Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. ( Freeman, D; McNamara, PJ; Sahni, M; Shivananda, SP; Taddio, A, 2013) |
| " The aim of the present study was to examine the impact of a novel NHE1 inhibitor, sabiporide, on cardiovascular function, blood oxygen transportation, and inflammatory response in an experimental model of metabolic acidosis produced by hemorrhage-induced hypovolemia followed by an infusion of lactic acid." | 3.79 | Sabiporide improves cardiovascular function, decreases the inflammatory response and reduces mortality in acute metabolic acidosis in pigs. ( Abraham, WM; Kraut, JA; Wu, D, 2013) |
| "The experiments test if experimental PE causes red blood cell hemolysis, arginase release and depletion of l-arginine and determine if arginase inhibition preserves l-arginine and improves pulmonary hemodynamics during PE." | 3.78 | Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism. ( Das, SK; Fulkerson, MB; Gellar, MA; Kline, JA; Watts, JA, 2012) |
| "The present study is an attempt to leverage therapeutic benefits of curcumin in pulmonary hypertension by encapsulating it in biodegradable poly(lactide-co-glycolic) acid nanoparticles." | 3.78 | Tissue localization of nanoparticles is altered due to hypoxia resulting in poor efficacy of curcumin nanoparticles in pulmonary hypertension. ( Devadasu, VR; Ravi Kumar, MN; Wadsworth, RM, 2012) |
| "Levosimendan did not attenuate endotoxin-induced pulmonary hypertension and did not improve myocardial function." | 3.77 | No beneficial effects of levosimendan in acute porcine endotoxaemia. ( Bendall, J; Chew, MS; Hawthorne, WJ; Huang, S; McLean, A; Simond, D; Ting, I; Whereat, S, 2011) |
| "This study demonstrates that exogenous ADM prevents and reverses hypodynamic circulation, attenuates pulmonary hypertension, and limits lactic acidosis in ovine endotoxaemia." | 3.74 | Exogenous adrenomedullin prevents and reverses hypodynamic circulation and pulmonary hypertension in ovine endotoxaemia. ( Booke, M; Ertmer, C; Hucklenbruch, C; Lange, M; Morelli, A; Rehberg, S; Van Aken, H; Westphal, M, 2007) |
| "64) l x min(-1)] and mean VO2 at lactic acidosis threshold [LAT, 0." | 3.70 | Gas exchange responses to continuous incremental cycle ergometry exercise in primary pulmonary hypertension in humans. ( Brundage, BH; Engelen, MP; Pórszász, J; Riley, MS; Wasserman, K, 2000) |
| " A diagnosis of idiopathic lactic acidosis was established when the arterial blood pH was found to be 6." | 3.64 | THE CLINICAL SIGNIFICANCE OF ELEVATED BLOOD LACTATE. ( PHILLIPSON, EA; SPROULE, BJ, 1965) |
| "The practice of treating PAH patients with oral or intravenous sildenafil suffers from the limitations of short dosing intervals, peripheral vasodilation, unwanted side effects, and restricted use in pediatric patients." | 1.46 | Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). ( Ahsan, F; McMurtry, IF; Nozik-Grayck, E; Patel, B; Rashid, J; Stenmark, KR, 2017) |
| " Polymeric porous particles of PGE1 produced the same effects at a reduced dosing frequency compared to plain PGE1 and caused minimal off-target effects on systemic hemodynamics." | 1.39 | Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency. ( Ahsan, F; Gupta, N; Gupta, V; Komatsu, M; McMurtry, IF; Mehvar, R; Nozik-Grayck, E; Oka, M; Shaik, IH, 2013) |
| "In a porcine endotoxin shock model, the mixed nonpeptide endothelin receptor antagonist bosentan was administered 2 h after onset of endotoxemia (n = 8)." | 1.30 | Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan. ( Alving, K; Oldner, A; Rudehill, A; Sollevi, A; Wanecek, M; Weitzberg, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia, MVF | 1 |
| Souza, R | 1 |
| Costa, ELV | 1 |
| Fernandes, CJCS | 1 |
| Jardim, CVP | 1 |
| Caruso, P | 1 |
| Zante, B | 1 |
| Reichenspurner, H | 1 |
| Kubik, M | 1 |
| Kluge, S | 1 |
| Schefold, JC | 1 |
| Pfortmueller, CA | 1 |
| Alruwaili, N | 1 |
| Kandhi, S | 1 |
| Sun, D | 1 |
| Wolin, MS | 1 |
| Gupta, V | 3 |
| Gupta, N | 1 |
| Shaik, IH | 1 |
| Mehvar, R | 1 |
| Nozik-Grayck, E | 2 |
| McMurtry, IF | 2 |
| Oka, M | 1 |
| Komatsu, M | 1 |
| Ahsan, F | 4 |
| Ishihara, T | 2 |
| Hayashi, E | 1 |
| Yamamoto, S | 1 |
| Kobayashi, C | 1 |
| Tamura, Y | 1 |
| Sawazaki, R | 1 |
| Tamura, F | 1 |
| Tahara, K | 1 |
| Kasahara, T | 1 |
| Takenaga, M | 1 |
| Fukuda, K | 1 |
| Mizushima, T | 1 |
| Rashid, J | 1 |
| Patel, B | 1 |
| Stenmark, KR | 1 |
| Rawat, A | 1 |
| Chew, MS | 1 |
| Hawthorne, WJ | 1 |
| Bendall, J | 1 |
| Whereat, S | 1 |
| Huang, S | 1 |
| Ting, I | 1 |
| Simond, D | 1 |
| McLean, A | 1 |
| Davis, M | 1 |
| Hope-Weeks, LJ | 1 |
| Beck-Broichsitter, M | 1 |
| Kleimann, P | 1 |
| Gessler, T | 1 |
| Seeger, W | 1 |
| Kissel, T | 1 |
| Schmehl, T | 1 |
| Watts, JA | 1 |
| Gellar, MA | 1 |
| Fulkerson, MB | 1 |
| Das, SK | 1 |
| Kline, JA | 1 |
| Devadasu, VR | 1 |
| Wadsworth, RM | 1 |
| Ravi Kumar, MN | 1 |
| McNamara, PJ | 1 |
| Shivananda, SP | 1 |
| Sahni, M | 1 |
| Freeman, D | 1 |
| Taddio, A | 1 |
| Wu, D | 1 |
| Kraut, JA | 1 |
| Abraham, WM | 1 |
| Nirmalan, M | 1 |
| Willard, T | 1 |
| Edwards, DJ | 1 |
| Dark, P | 1 |
| Little, RA | 1 |
| PHILLIPSON, EA | 1 |
| SPROULE, BJ | 1 |
| Huang, JH | 1 |
| Su, ZK | 1 |
| Wang, SM | 1 |
| Ertmer, C | 1 |
| Morelli, A | 1 |
| Rehberg, S | 1 |
| Lange, M | 1 |
| Hucklenbruch, C | 1 |
| Van Aken, H | 1 |
| Booke, M | 1 |
| Westphal, M | 1 |
| Wanecek, M | 1 |
| Oldner, A | 1 |
| Rudehill, A | 1 |
| Sollevi, A | 1 |
| Alving, K | 1 |
| Weitzberg, E | 1 |
| Lorente, JA | 1 |
| Delgado, MA | 1 |
| Tejedor, C | 1 |
| Mon, E | 1 |
| Hervás, M | 1 |
| Pascual, T | 1 |
| Fernández-Segoviano, P | 1 |
| Rieppi, G | 1 |
| Soler, A | 1 |
| Ayuso, D | 1 |
| Esteban, A | 1 |
| Riley, MS | 1 |
| Pórszász, J | 1 |
| Engelen, MP | 1 |
| Brundage, BH | 1 |
| Wasserman, K | 1 |
1 review available for lactic acid and Pulmonary Hypertension
| Article | Year |
|---|---|
Metabolism and Redox in Pulmonary Vascular Physiology and Pathophysiology.
Topics: Animals; Blood Vessels; Cyclic GMP; Glucosephosphate Dehydrogenase; Glycolysis; Humans; Hypertension | 2019 |
2 trials available for lactic acid and Pulmonary Hypertension
| Article | Year |
|---|---|
Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide.
Topics: Administration, Inhalation; Bronchodilator Agents; Cardiac Output; Echocardiography; Half-Life; Huma | 2013 |
Near-infrared spectroscopy monitoring of brain oxygen in infant cardiac surgery.
Topics: Biomarkers; Brain; Brain Injuries; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Circulatory | 2007 |
18 other studies available for lactic acid and Pulmonary Hypertension
| Article | Year |
|---|---|
Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit.
Topics: Adult; Brazil; Cohort Studies; Female; Hospital Mortality; Humans; Hypertension, Pulmonary; Intensiv | 2021 |
Base excess is superior to lactate-levels in prediction of ICU mortality after cardiac surgery.
Topics: Aged; Cardiopulmonary Bypass; Female; Hospital Mortality; Humans; Hyperlactatemia; Hypertension, Pul | 2018 |
Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.
Topics: Administration, Inhalation; Alprostadil; Animals; Delayed-Action Preparations; Disease Models, Anima | 2013 |
Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension.
Topics: Animals; Capillary Permeability; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; | 2015 |
Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).
Topics: Administration, Inhalation; Administration, Oral; Animals; Drug Carriers; Humans; Hypertension, Pulm | 2017 |
Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension.
Topics: Administration, Inhalation; Alprostadil; Animals; Bronchoalveolar Lavage; Cell Line; Cell Survival; | 2010 |
No beneficial effects of levosimendan in acute porcine endotoxaemia.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Cytokines; Echocardiography; Endotoxemia; Heart Functio | 2011 |
PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Alprostadil; Animals; Antihypertensive Agents; beta-Cyclodextrins | 2011 |
Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization.
Topics: Administration, Inhalation; Aerosols; Antihypertensive Agents; Chemistry, Pharmaceutical; Delayed-Ac | 2012 |
Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism.
Topics: Animals; Arginase; Arginine; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Enzym | 2012 |
Tissue localization of nanoparticles is altered due to hypoxia resulting in poor efficacy of curcumin nanoparticles in pulmonary hypertension.
Topics: Administration, Oral; Animals; Curcumin; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hy | 2012 |
Sabiporide improves cardiovascular function, decreases the inflammatory response and reduces mortality in acute metabolic acidosis in pigs.
Topics: Acidosis; Animals; Cardiovascular System; Cation Transport Proteins; Familial Primary Pulmonary Hype | 2013 |
Effects of sustained post-traumatic shock and initial fluid resuscitation on extravascular lung water content and pulmonary vascular pressures in a porcine model of shock.
Topics: Animals; Blood Pressure; Cardiac Output; Disease Models, Animal; Extravascular Lung Water; Female; F | 2003 |
THE CLINICAL SIGNIFICANCE OF ELEVATED BLOOD LACTATE.
Topics: Acidosis; Acidosis, Lactic; Blood; Chemical Phenomena; Chemistry; Geriatrics; Humans; Hypertension; | 1965 |
Exogenous adrenomedullin prevents and reverses hypodynamic circulation and pulmonary hypertension in ovine endotoxaemia.
Topics: Acidosis, Lactic; Adrenomedullin; Animals; Cardiac Output; Drug Evaluation, Preclinical; Endotoxemia | 2007 |
Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan.
Topics: Acid-Base Imbalance; Animals; Bosentan; Cardiovascular Diseases; Endothelin Receptor Antagonists; En | 1997 |
Modulation of systemic hemodynamics by exogenous L-arginine in normal and bacteremic sheep.
Topics: Acidosis; Animals; Arginine; Bacteremia; Blood Gas Analysis; Blood Pressure; Disease Models, Animal; | 1999 |
Gas exchange responses to continuous incremental cycle ergometry exercise in primary pulmonary hypertension in humans.
Topics: Acidosis, Lactic; Adult; Case-Control Studies; Exercise; Exercise Test; Female; Heart Failure; Human | 2000 |